Bangalore, India, August 19, 2019: With its recently published study “Global Alzheimer’s Therapeutics Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global market for Alzheimer’s therapeutics is expected to witness single-digit growth during the forecast period 2019–2025. As of now, there are five drugs approved by US FDA for the treatment of Alzheimer's symptoms momentarily assisting memory and thinking difficulties. However, these drugs will not treat or prevent the development of the root cause of the disease.

Access Full Report Summary @ https://www.infoholicresearch.com/report/alzheimers-therapeutics-market/

Many developmental drugs strive to break the disease cycle itself through impacting several Alzheimer-related brain modifications. These modifications will help delay or prevent the disease progression. Researchers think that effective therapy will eventually require a mixture of drugs aiming multiple targets.

Get a sample copy of the report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=14474

By 2025, prevention and treatment of Alzheimer's disease is expressed as an objective of the government of US and is supported by other nations. At NIH, the National Institute on Aging (NIA) supports study initiatives on Alzheimer's by the federal government. NIA-supported Alzheimer's Disease Research Centers are pursuing a wide spectrum of study all around the US including studies of Alzheimer's symptoms, diagnosis, and management. NIA also funds the Alzheimer's Clinical Trials Consortium to speed and grow Alzheimer's and allied research and therapies on dementia.

“Expensive and ambitious efforts made by the pharmaceutical companies to find an efficient therapy for Alzheimer's have repeatedly failed. Drugs that appeared promising in early trials have failed to prove its efficiency when tested in large groups. In 2018, Pfizer Inc. discontinued its clinical trials to discover Alzheimer's therapies, thus closing its studies on both Alzheimer's and Parkinson's disease and reducing some 300 employees in that context. In March 2019, a couple of stage 3 clinical studies with severe behavioral deterioration due to Alzheimer's disease or severe Alzheimer's illness syndrome were abruptly suspended by Biogen and its Japanese affiliate Eisai,” pointed out Rikitha K Murthy, Senior Research Analyst, Infoholic Research

Key Segments of the Report Include:

• Molecule Type:
  • Cholinesterase Inhibitors           
  • NMDA Receptor Antagonists      
  • Others
• Distribution Channel:
  • Hospital Pharmacies      
  • Retail Pharmacies
  • E-Pharmacies

• Industry outlook: Market trends, drivers, restraints, and opportunities

Contact: